MBX Biosciences, Inc.
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M |
| Total Depreciation and Amortization | 50.00K | 61.00K | 77.00K | 58.00K | 75.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.54M | 998.00K | 525.00K | 118.00K | 632.00K |
| Change in Net Operating Assets | -1.51M | 918.00K | 600.00K | -627.00K | 2.77M |
| Cash from Operations | -21.54M | -17.43M | -22.68M | -16.04M | -14.66M |
| Capital Expenditure | -399.00K | -707.00K | -30.00K | -92.00K | -57.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.46M | 26.69M | 3.26M | -67.25M | -100.73M |
| Cash from Investing | 17.06M | 25.99M | 3.23M | -67.35M | -100.79M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 188.08M | 1.33M | 4.00K | 195.00K | 174.51M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 63.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -254.00K | -- | -- | -327.00K | -2.20M |
| Cash from Financing | 187.82M | 1.33M | 4.00K | -132.00K | 235.81M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 183.34M | 9.88M | -19.45M | -83.51M | 120.36M |